# First Successful Treatment Reported with Pembrolizumab in a Patient Diagnosed with Choriocarcinoma in Hungary

## TL;DR

This paper reports the first successful use of pembrolizumab, an immunotherapy drug, to treat a rare and aggressive cancer called choriocarcinoma in Hungary.

## Contribution

The novelty is the first successful treatment of ultra-high-risk choriocarcinoma with a PD-1 inhibitor in Hungary.

## Key findings

- Pembrolizumab treatment led to a successful outcome in a stage IV choriocarcinoma patient.
- The patient showed a positive response to immunotherapy after failing standard chemotherapy.
- This case highlights the potential of PD-1 inhibitors in treating chemoresistant choriocarcinoma.

## Abstract

Pembrolizumab is a programmed cell death protein (PD-1) inhibitor, humanized antibody widely used in cancer immunotherapy. Choriocarcinoma is an aggressive type of gestational trophoblastic neoplasia. Its treatment is based on surgical removal of the tumorous tissue and systemic chemotherapy; however, in some chemoresistant cases, immunotherapy can also be a valid option. Here, we report the first successful programmed death inhibitor-based treatment of a patient diagnosed with stage IV, ultra-high-risk choriocarcinoma in Hungary.